The Company and Boyle also entered into a consulting agreement, effective January 1, 2024, pursuant to which Boyle will continue providing strategic and advisory services to the company. The Consulting Agreement will continue for a period of six months.
On December 22, 2023, Alaunos Therapeutics Entered Into Separation And Release Agreement With CEO Kevin Boyle In Connection With Boyle's Termination - Filing
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.